Choice and dose of corticosteroid for antenatal treatments
Choice and dose of corticosteroid for antenatal treatments
复制标题
DOI：
10.1016/j.ajog.2004.01.044
复制
发表时间：
2004-04-01
影响因子：
9.8
通讯作者：
Soll, RF
中科院分区：
文献类型：
--
作者：
Jobe, AH;Soll, RF
虽然产前糖皮质激素是妊娠32至34周前有早产风险的妇女的标准护理，但皮质类固醇的选择和剂量尚未标准化。对试验数据的分析表明，倍他米松降低了新生儿死亡的风险，而地塞米松没有。其他临床数据也表明倍他米松是产前治疗的首选药物。糖皮质激素的药理学表明，每次治疗较低的糖皮质激素总剂量可能与目前推荐的治疗方法一样有效。然而，改变目前的做法需要进一步的随机对照试验。(C) 2004爱思唯尔公司版权所有。
Although antenatal glucocorticoids are standard of care for women at risk of preterm delivery before 32 to 34 weeks' gestation, the choice and dosing of the corticosteroid has not been standardized. An analysis of the trial data demonstrates that the risk of neonatal death is decreased with betamethasone, but not dexamethasone. Other clinical data also indicate that betamethasone is the drug of choice for antenatal treatment. The pharmacology of the corticosteroids suggests that a lower total glucocorticoid dose per treatment may be as effective as the current treatment recommendations. However, a change from current practice will require further randomized controlled trials. (C) 2004 Elsevier Inc. All rights reserved.